Sir, It seems extraordinary that your journal should carry a paper on the use of diazepam and a very potent drug, flupenthixol, for the treatment of such a mild, though occasionally intractable, condition as chronic muscle contraction headache, as described by Hackett et al. (November 1987 JRSM, p 689) .
Surely, in 1988, we know better than to use powerful and, in the case of diazepam, habit-forming substances for the treatment of simple illnesses. There are plenty of people in medicine today who would not prescribe a benzodiazepine under any circumstances1.
It is now very clear that the many and varied reactions of individuals to 'life stress' are best not treated by pharmacological agents, but by one of the many alternative approaches. This being so, the publication of research papers on the evaluation of drugs in the indication of chronic muscle contraction is not helpful to the furtherance of good medical practice. The author replies below: Sir, A number of factors emerged during our investigation of patients with muscle contraction headache attending neurology clinics. Firstly, the consumption of over-the-counter analgesics was very high and in some cases, as many as 55 tablets per week were being taken. This is, of course, associated Journal of the Royal Society of Medicine Volume 81 July 1988 429 whose bequest has among other things provided the Society's in-house computer which handles our financial control and membership record systems. Finally, as this is my last President's letter I wish to thank the members of Council who have made my term of office so pleasant and easy to bear. Mr Bob Thomson has been a tower of strength at the administrative helm and over the past two years he has greatly improved the workings of the Society by his meticulous attention, not only to the broad spectrum of his duties but also to the minutiae of day to day management.
Sir Gordon Robson
President Royal Society of Medicine April 1988 with a high level of morbidity from peptic ulceration and gastrointestinal bleeding. We do not have to think very hard, in general practice, to find patients who have experienced such problems caused by the ingestion of such analgesics taken for 'mild' conditions. It was also of interest that of 40 patients attending our neurology clinic, 32 had previously been treated by their GP, with either a benzodiazepine or tricyclic analgesic for their muscle contraction headaches. At an initial review of the prescribing habits of the 3 consultants within the department, it was clearly found to be standard practice that when a serious cause for headache had been excluded, the patient was discharged to their GP, with a suggestion that a benzodiazepine be used to provide symptomatic relief. I share Dr Walden's concern about the overprescribing of benzodiazepines and, indeed, I think our paper serves to prove that they are ineffective agents with which to treat muscle contraction headache and, hopefully, further clinical evidence will result in their not being prescribed for this condition. In the paper, I did mention some of the many alternative approaches, but I am afraid the majority of neurologists who I have met, do not share Dr Walden's enthusiasm for such methods as biofeedback and relaxation techniques. Having gone through a period of enthusiasm for these therapies, I have found particularly in the north west of England, that it is very difficult to obtain the services of skilled biofeedback technicians and relaxation therapists and invariably when I do, the patient only attends on one or, at the most, two sessions. Likewise, tapes may be played a similar number of times and then discarded. Certainly Diamond in his 'Practising physicians' approach to headache' considers at great length pharmacological agents and acknowledges the reality of their place in prophylaxis, although for certain well motivated individuals, the techniques that Dr Walden considers, may be beneficial. I cannot see in my lifetime, that the supply of technicians in these fields will increase sufficiently to make them readily available for my patients and, I am sure, very little of the Government's injection of cash into the NHS, will be devoted to this field. It is, however, good to see that physicians practising in centres of excellence remain enthusiastic about such techniques.
On the subject offlupenthixol, the ABPI Data Sheet Compendium 1987, states that; 'Clinical trials have shown symptoms of apathy, lowered mood, asthenia; despondency, lack of initiative and inertia are likely to respond well to flupenthixol and that its high therapeutic index is an advantage in view of the suicide risk associated with depressive illness.' My colleagues and I have used flupenthixol in mild depressive conditions in general practice at doses of 0.5-1 mg daily in short courses (usually lasting less than 6 weeks) and have found no problems with tardive dyskinesia. We would, of course, acknowledge that larger doses used for longer periods of time may lead to such problems. I feel, however, that our paper does highlight all these points and emphasizes the low dosage and the duration of courses of treatment. Any screening test should be cheap, specific and sensitive. As indicated by Flanagan et al. the determination of the anion gap by calculation has no intrinsic cost, but this only holds true if the population being screened is already having plasma electrolyte determinations for some other reason. It also assumes that plasma chloride is among the parameters being profiled, which is by no means always the case.
If a test has high specificity and sensitivity, by definition its use should result in few false positive and false negative categorizations. Any cause of hypoproteinaemia may be associated with a reduced anion gap in the absence of myeloma. In addition, the overlapping distributions of anion gaps in the healthy population and in patients with myeloma, and particularly those patients with IgA paraproteinaemia, would make it difficult to interpret a 'normal' result. Because the depressed anion gap, in some patients with myeloma, is in part dependent on the magnitude of the paraproteinaemia, early disease may easily be missed.
The authors mention other simple haematological screening tests for myeloma, including ESR and background staining as a blood film, but they fail to discuss the use of simple and cheap biochemical indices, such as the measurement of serum total protein and albumin.
Renal impairment is a common feature of malignant paraproteinaemia. The associated increase in anion gap would tend to off-set the reduction related to the myeloma, and would therefore be a cause for a false negative result. Flanagan et al. do not mention what proportion of their patient group was so affected.
Elderly subjects do indeed have a high prevalence of myeloma, and perhaps they should be screened for this disease. However, estimation of total serum protein and albumin, with a derived estimate of serum gamma-globulins, followed by serum protein electrophoresis and immunofixation, would appear to be the most logical diagnostic approach. suggest that the anion gap may be useful as a screening test for myeloma in the elderly, and that this procedure has no intrinsic cost.
The predictive value of a low anion gap for myeloma is not given, but can be calculated from published datal using Bayes' theorern'', The probability of myeloma in the general population of Cumbria is 0.00026 3 . If every patient with this disease has a low anion gap, this can be compared to the probability of a low anion gap occurring from other causes. A study of 39 360 patients' found a low anion gap at least once in 304 (probability=0.0077) including one case of myeloma. Thus the probability of a patient with a low anion gap having myeloma is 0.00026/0.0077, ie 0.034. Accordingly, 97% of patients with a low anion gap do not have myeloma and 'no intrinsic cost' becomes inflated by the 'need for more specific investigation'.
Multichannel continuous-flow analysers can produce a great deal of unsolicited data. Any procedure that extracts clinically useful information from this at no extra cost is worthwhile. The early diagnosis of myeloma is highly desirable. However, with a trend towards discretionary analysis, it is doubtful whether these figures justify the real cost of including the anion gap in a biochemical profile. T J DAVIES Assessment of self-poisoning patients by psychiatrists and junior medical staff Sir, The study of assessment in one particular casualty unit by Creed and Black (February 1988 JRSM, p 97) highlights the advantages and shortfalls in care of patients treated wholly in out-patient units as compared with those assessed while they are inpatients.
The challenge raised in the last paragraph could well be answered, to the advantage of all, by a nationwide duplication of the near-ideal system in Sunderland District General Hospital (catchment 350000 urban to 500 000 total, including hinterland) where all self-poisoning or self-harming patients are treated, for the acute situation, in the out-patient unit, swiftly admitted to the 22-bedded accident/emergency ward, maintained under (now fairly expert) ward nursing staff, and seen next day (or sooner if necessary) by the senior accident/emergency staff, consultants or senior registrars (that cadre which, on
